An Introduction to Stroke
The majority of strokes (85%) are caused by acute ischaemia resulting from the blockage of a cerebral artery, leading to a loss of oxygenation in downstream brain tissue, and ultimately causing neuronal cell death and irreversible neurological damage. The remainder are haemorrhagic strokes, caused by intracerebral haemorrhage or subarachnoid haemorrhage. The treatment of ischaemic stroke has been transformed by advances in imaging technology, as well as the emergence of thrombolytic therapy and subsequent mechanical thrombectomy, sometimes facilitating complete recovery. The increasing use of direct oral anticoagulants is preventing stroke in patients with atrial fibrillation. Therapies targeting neuroinflammation after brain ischaemia, such as transplantation of mesenchymal stem cells, are also emerging as a potentially useful treatment option.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Patent Foramen Ovale Closure—Addressing the Unmet Need for Reducing the Risk of Ischemic Stroke
US Neurology. 2020;16(1):54–60
Globally, a high proportion (around 25%) of transient ischemic attacks (TIAs) and ischemic strokes are cryptogenic.1,2 The Trial of ORG 10172 in Acute Stroke Treatment (TOAST) classification defines a cryptogenic stroke as a brain infarction that is not caused by definite cardioembolism, large artery atherosclerosis, or small artery disease, despite extensive investigations.3 The “ASCOD” classification defines strokes […]
Atrial Fibrillation and Dementia
European Journal of Arrhythmia & Electrophysiology. 2020;6(1):10-6 DOI: https://doi.org/10.17925/EJAE.2020.6.1.10
Atrial fibrillation (AF) is one of the most common arrhythmias. It affected 33.5 million people worldwide in 2010, a number that is expected to double by 2050.1 AF prevalence increases with age, and approximately 25% of individuals aged 40 years or older will develop AF during their lifetime.2,3 Irrespective of age, AF incidence also increases with diabetes […]
Andexanet Alfa and its Clinical Application
Heart International. 2020;14(1):20-3 DOI: https://doi.org/10.17925/HI.2020.14.1.20
The factor Xa (FXa) inhibitors apixaban, rivaroxaban and edoxaban, together with the thrombin inhibitor dabigatran, are collectively referred to as non-vitamin K antagonist (or direct) oral anticoagulants (NOACs). FXa inhibitors are widely used for stroke prevention in patients with nonvalvular atrial fibrillation,1 and for the treatment and prevention of deep vein thrombosis and pulmonary embolism.2,3 In patients […]
Aldo Pietro Maggioni, ESC 2019 – Oral Anticoagulants and Ischaemic Stroke in Atrial Fibrillation
We spoke to Dr Aldo Pietro Maggioni (Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) Research Center, Florence, Italy) about the key observations from his study of trends in oral anticoagulant use and the rate of ischaemic stroke in people with atrial fibrillation. He also discussed how big data can provide insight and what he expects to […]
Novel Oral Anticoagulants – Do Real-world Data Support our Expectations?
European Journal of Arrhythmia & Electrophysiology. 2019;5(1):48-58 DOI: https://doi.org/10.17925/EJAE.2019.5.1.48
Atrial fibrillation (AF) is one of the most common cardiac diseases in elderly patients and is associated with increased morbidity and mortality. It is of great importance to treat patients with AF with oral anticoagulants (OACs) to prevent ischaemic strokes, which represents the most relevant complication of AF. For many decades, vitamin K antagonists (VKAs) […]
Current Endocardial Approaches for Left Atrial Appendage Closure
European Journal of Arrhythmia & Electrophysiology. 2019;5(1):40-6 DOI: https://doi.org/10.17925/EJAE.2019.5.1.40
Atrial fibrillation (AF) is the most commonly encountered sustained arrhythmia and its prevalence and incidence are on the rise as the aging of the population increases.1 AF has been described as an emerging epidemic of cardiovascular disease, with significant effects on estimated disability and mortality, and is rapidly turning into a major public health concern. […]
Improved Dosing and Administration of Rivaroxaban when Prescribed by a Cardiologist
Heart International. 2019;13(1):24–7 DOI: https://doi.org/10.17925/HI.2019.13.1.24
Rivaroxaban is a direct factor Xa inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF), treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). Furthermore, it is prescribed for risk reduction and prophylaxis for DVT and PE following hip or knee replacement surgery and […]
Purvi Parwani, Mamas Mamas, Martha Gulati, ESC 2018 – Social Media and Cardiology
Dr Purvi Parwani (Assistant Professor of Medicine, Loma Linda University Health, Loma Linda, CA, USA), Professor Mamas Mamas (Professor of Cardiology, University of Keele, Keele, UK) and Dr Martha Gulati (Head of Cardiology, University of Arizona College of Medicine, Phoenix, AZ, USA) discuss social media in cardiology. Filmed at ESC 2018, Munich. View more content […]
102/Prevention of AF related stroke through appropriate treatment with anticoagulation – a new centralised pharmacist model in Haringey primary care networks
European Journal of Arrhythmia & Electrophysiology. 2020;6(Suppl. 1):abstr102
Introduction: Clinical pharmacists are a new workforce in Primary Care Networks (PCN) and can play a critical role in realising the NHS Long Term Plan ambition, principally through secondary prevention.1 A centralised pharmacist model was implemented in the delivery of the NHSE Atrial Fibrillation (AF) patient optimisation demonstrator programme 2018-2020 aimed at preventing AF related stroke […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!